
Health Canada Approves Durvalumab Monotherapy for Limited-Stage Small Cell Lung Cancer
Health Canada has granted a notice of compliance for durvalumab (Imfinzi) as monotherapy for the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy.1 …